尾部圆润、自然舒展。东风日产NX8搭载全球最多2064颗OLED「量子光幕」尾灯，支持自定义灯语， 展现魅力科技感，显著提升辨识度。 作为中大型新能源SUV，东风日产NX8采用800V高压平台和全新一代宁德时代（300750）磷酸铁锂电 芯的云盾电池。 而800V+5C超充技术，具备充电超快特性，并做到-30℃~60℃全温域覆盖，此外，东风日产NX8正式搭 载激光雷达，在高速领航辅助NOA、城市领航辅助NOA、全场景智能辅助泊车等高阶智驾功能上全面 进阶。 据悉，东风日产NX8将于2026年上半年正式亮相。 日前，东风日产全新中大型SUV NX8公告图正式发布。从命名来看，NX8是东风日产新能源N序列下 （N），定位中大型（8）的探索跨界SUV（X）。它的到来，将与纯电轿车N7、插混轿车N6等车型一 起，打造更加完整的东风日产"新能源全家桶"产品矩阵。 据公告图披露信息，东风日产NX8尺寸为4870×1920×1680mm，轴距2917mm，拥有最主流、最适合家 庭的中大型SUV尺寸。 外观上，东风日产NX8以家庭未来美学打造极致简洁外观和纯粹无瑕车身，符合家庭SUV未来设计形 态。东风日产NX8沿袭日产家族 ...

Core Viewpoint - The company emphasizes that its product, Jin Jiu, is a health wine with "immune regulation and anti-fatigue" functions, but it is not a medicine and should be consumed in moderation, especially for women during their menstrual period or when feeling unwell [1] Group 1 - The official account of the company released a statement on December 7, highlighting the health benefits of Jin Jiu while clarifying that it is not a substitute for medicine [1] - There was public concern regarding the promotion of Jin Jiu as a health product, with comments in the social media suggesting that some individuals are misrepresenting its benefits [1] - The company responded to these concerns by stating that they are aware of the discussions but clarified that the misleading information is not from official sources [1] Group 2 - The product gained significant attention this week, being referred to as "the menstrual miracle water," which led to it trending on social media [1]

#五粮液回应降价传闻#【#公司回应第八代五粮液开票价降至900元#】有市场消息称，2026年五粮液将 对核心单品52度第八代五粮液调整价格 ——在1019元/瓶的出厂价基础上给予折扣，经销商开票直降119 元，为900元/瓶；若叠加费用支持、返利等政策，该单品经销商端实际成本甚至可低至800多元/瓶。针 对此消息，记者第一时间联系五粮液方面。公司明确回应，第八代五粮液1019元/瓶的出厂价并未调 整，市场所传 "降价"，实为公司相关补贴支持政策落地后的价格变化。（每经） ...

Group 1 - Shoulv Hotel announced the resignation of Deputy General Manager Zhang Shujuan due to personal reasons, effective November 30, 2025 [1] - China State Construction Engineering Corporation issued the first commercial office complex real estate asset-backed securities (ABS) in the country, with a scale of 1.246 billion yuan, backed by the Shanghai Zhongjian Plaza project [1] - Fosun Tourism Group launched its HiSphere brand for urban cultural tourism malls, with the first project "Hi·Chongqing" signed, expected to open in the second half of 2026 [1] Group 2 - Joy City Holdings' subsidiary Wuhan Diyue filed a lawsuit against the Natural Resources and Urban-Rural Development Bureau of Wuhan's Caidian District over an administrative agreement dispute [2] - The lawsuit seeks to terminate the land use rights transfer contract signed on December 31, 2019, and demands the return of 360 million yuan in land transfer fees and compensation totaling 713 million yuan for losses incurred [3] Group 3 - The "Wai Li" international commercial entertainment complex is set to officially open on December 26, featuring major components like Wangfujing WellTown and Nuo Lan Hotel, with over 500 brands expected to be introduced [4] - In Q3 2025, 51 listed cultural tourism companies reported a combined revenue of approximately 83.993 billion yuan, with 33 companies profitable and 18 at a loss, indicating a predominance of profitability in the sector [5][6]

根据最新的市场汇算数据，大约价值1343.36万元人民币。 近日，湖北咸宁市嘉鱼公安发布公告，寻找一笔涉敲诈勒索案的虚拟货币原主人，虚拟货币钱包内共有 USDT币约190万枚。 ...

Core Insights - The 2025 Digital Intelligence Technology Ecological Conference was held in Guangzhou, showcasing Huawei's innovations in smart terminals and intelligent ecosystems, emphasizing the theme "Smart Navigation, Intelligent Coexistence" [1][5] Group 1: Exhibition Highlights - Huawei's exhibition area covered 468 square meters, featuring a "1+8" product matrix, HarmonyOS intelligent vehicles, and comprehensive smart home solutions [1] - The exhibition design was highly technological, with distinct areas for product displays, including the 1+8 product display table, HarmonyOS intelligent vehicle area, and smart home solutions [2][3] Group 2: Product Innovations - The HUAWEI Mate XTs showcased a lightweight foldable design with a near-crease-free screen, enhancing portability and durability [2] - The HUAWEI Mate80 series offered significant upgrades in performance and imaging, featuring a new processor and advanced imaging systems for professional-grade photography [2] - The HUAWEI WATCH Ultimate 2 provided real-time health monitoring and a new adventure mode for outdoor safety [3] - The HUAWEI MateBook Fold featured a versatile foldable screen design, enhancing user experience across different scenarios [3] Group 3: Intelligent Automotive Solutions - The HarmonyOS intelligent cockpit in three showcased models (Wenjie M9, Xiangjie S9, Zhijie R7) enabled seamless connectivity with personal devices, enhancing user experience [4] - Advanced driving assistance systems in these vehicles provided features like automatic avoidance, lane keeping, and smart parking for safer driving [4] Group 4: Smart Home and Enterprise Solutions - The HarmonyOS smart home solutions allowed users to control home devices remotely, enhancing convenience and security [4] - Huawei's enterprise solutions aimed to improve operational efficiency and reduce costs for businesses through digital transformation [4][5]

Core Insights - The article highlights the significant growth in China's automobile exports to countries along the "Belt and Road" initiative, with a total export value of $115.68 billion from January to October 2025, marking a year-on-year increase of 13.8% [1] - The export of complete vehicles reached 4.414 million units, reflecting a year-on-year growth of 23.2% [1] - Exports of new energy vehicles (NEVs) surged to 1.418 million units, showing a remarkable year-on-year increase of 76.2% [1] Summary by Category - **Export Value** - Total export value to "Belt and Road" countries reached $115.68 billion, up 13.8% year-on-year [1] - This figure accounts for 59.6% of China's total automobile exports [1] - **Complete Vehicle Exports** - Exports of complete vehicles totaled 4.414 million units, representing a 23.2% increase compared to the previous year [1] - **New Energy Vehicle Exports** - Exports of new energy vehicles reached 1.418 million units, with a significant growth of 76.2% year-on-year [1]

【#茅台原董事长张德芹新任职#】12月5日，贵州省工商联工作人员向红星资本局确认，贵州茅台原董 事长张德芹已赴贵州省工商业联合会上任，分管党组工作。10月25日上午，茅台集团宣布，张德芹不再 担任茅台集团董事长职务，另作他任。2024年4月，张德芹接任丁雄军，成为茅台集团董事长及上市公 司贵州茅台董事长，在任时间一年半。（红星新闻） ...

（企业公告） 截止到2025年11月底，塔斯汀在营门店数11124家。2025年1-11月闭店数为67家，迁址店数为238家。该第三方数据监 测平台在发布数据前，从未与品牌进行任何沟通和核实。 12月5日，塔斯汀发布声明。表示近期媒体涉及品牌加盟数据的相关报道中，引用了"极海品牌监测"关于塔斯汀的开闭 店数据,该数据严重失实。 对"极海品牌监测"及其他第三方平台发布失实数据的行为，塔斯汀保留追究法律责任的权利。 ...

Core Viewpoint - The company has decided to delay the global offering and listing of its H-shares due to market conditions, with a commitment to timely information disclosure regarding future developments [1] Group 1: Financial Performance and Collaborations - The significant increase in net profit for 2024 is primarily attributed to a major licensing collaboration with BMS, raising concerns about the sustainability of long-term profitability due to potential "one-time revenue" perceptions [1] - The company has received an upfront payment of $800 million from BMS, which is non-refundable and non-offsettable, with actual amounts subject to bank fees [1] - The company is eligible for additional payments of up to $250 million for recent or contingent milestones, and up to $7.1 billion for achieving specific development, registration, and sales milestones [1] Group 2: Clinical Development Pipeline - The company has successfully developed three core clinical assets in Phase III (iza-bren, T-Bren, and SI-B001) and 14 early-stage core clinical assets, including 8 ADC drugs and 4 GNC drugs [2] - Over 90 clinical trials are being conducted globally, with more than 80 trials in China and 10 in the United States [2] Group 3: Specific Drug Developments - Iza-bren is a first-in-class dual-target ADC that has initiated over 40 clinical trials for more than 10 types of tumors, with significant trials ongoing in both the U.S. and China [3] - T-Bren is an innovative ADC targeting HER2, currently undergoing 14 clinical trials, including 5 Phase III trials, demonstrating significant anti-tumor efficacy [4]